Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Clinical trial NCT05092451 · RECRUITING

Trial details

NCT number: NCT05092451
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-Cell Lymphoma Myelodysplastic Syndromes (MDS)Acute Myeloid Leukemia (AML)Multiple Myeloma Plasma Cell Leukemia Hodgkin Lymphoma T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia Blastic Transformation of Chronic Myeloid Leukemia Germ Cell Tumors

Start date: 2022-11-01
Primary completion: 2030-08-31
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.